ACAD — ACADIA Pharmaceuticals Inc. stock price, charts and financials
QT78ACADIA Pharmaceuticals Inc.ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 12.29 | EPS (ttm) | 2.22 | Insider Own | 46.92% | Shs Outstand | 171.24M | Perf Week | -1.94% |
| Market Cap | 4.67B | Forward P/E | 29.80 | EPS next Y | 0.92 | Insider Trans | -0.11% | Shs Float | 169.05M | Perf Month | -9.67% |
| Enterprise Value | 3.78B | PEG | 0.28 | EPS next Q | 0.21 | Inst Own | - | Short Float | 5.76% | Perf Quarter | 26.23% |
| Income | 382.00M | P/S | 4.10 | EPS this Y | -72.15% | Inst Trans | - | Short Ratio | 6.01 | Perf Half Y | 31.71% |
| Sales | 1.14B | P/B | 3.58 | EPS next Y | 48.14% | ROA | 21.83% | Short Interest | 9.74M | Perf YTD | 2.17% |
| Book/sh | 7.63 | P/C | 4.89 | EPS next 5Y | 43.95% | ROE | 32.39% | 52W High | 30.96 -11.85% | Perf Year | 12.77% |
| Cash/sh | 5.58 | P/FCF | 27.33 | EPS past 3/5Y | - | ROIC | 6.19% | 52W Low | 19.69 38.60% | Perf 3Y | 5.41% |
| Dividend Est. | - | EV/EBITDA | 32.56 | Sales past 3/5Y | 27.52% 19.39% | Gross Margin | 91.13% | Volatility | 2.96% 2.77% | Perf 5Y | 69.61% |
| Dividend TTM | - | EV/Sales | 3.32 | EPS Y/Y TTM | 63.24% | Oper. Margin | 7.59% | ATR (14) | 0.83 | Perf 10Y | -17.53% |
| Dividend Ex-Date | - | Quick Ratio | 3.30 | Sales Y/Y TTM | 18.89% | Profit Margin | 33.42% | RSI (14) | 43.80 | Recom | 2.32 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.39 | EPS Q/Q | 12.50% | SMA20 | -3.93% | Beta | 0.86 | Target Price | 33.83 |
| Payout | 0.00% | Debt/Eq | 0.04 | Sales Q/Q | 16.23% | SMA50 | -1.15% | Rel Volume | 3.21 | Prev Close | 27.45 |
| Employees | 797 | LT Debt/Eq | 0.03 | Earnings | Nov 04 | SMA200 | 10.84% | Avg Volume | 1.71M | Price | 27.29 |
| IPO Date | May 27, 2004 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 164.12% 3.85% | Net Debt/EBITDA | -2.68 | Volume | 5,482,709 | Change | -0.58% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-25-26 | Reiterated | Deutsche Bank | Buy | $37 → $38 |
| Aug-25-26 | Reiterated | Morgan Stanley | Equal Weight | $27 → $28 |
| Aug-17-26 | Reiterated | UBS | Buy | $40 → $49 |
| Aug-12-26 | Reiterated | Needham | Buy | $34 → $41 |
| Aug-10-26 | Reiterated | Morgan Stanley | Equal Weight | $26 → $27 |
| Aug-05-26 | Reiterated | Oppenheimer | Perform | $22 → $25 |
| Aug-05-26 | Reiterated | RBC Capital | Outperform | $36 → $37 |
| Jul-29-26 | Reiterated | Raymond James | Outperform | $15 |
| Jul-21-26 | Reiterated | BMO Capital | Outperform | $31 → $36 |
| Jul-07-26 | Reiterated | RBC Capital | Outperform | $31 → $36 |
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,139 | 1,072 | 958 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 101 | 89 | 82 | — | — | — | — | — | — | |
| Gross Profit | 1,038 | 983 | 876 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 620 | 549 | 488 | — | — | — | — | — | — | |
| Research and Development | 332 | 329 | 303 | — | — | — | — | — | — | |
| Other Operating Expense | -1 | 0 | -146 | — | — | — | — | — | — | |
| Operating Income | 86 | 105 | 231 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 36 | 34 | 27 | — | — | — | — | — | — | |
| Net Income Before Taxes | 121 | 139 | 258 | — | — | — | — | — | — | |
| Income Taxes | -259 | -252 | 32 | — | — | — | — | — | — | |
| Consolidated Net Income | 382 | 391 | 226 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 382 | 391 | 226 | — | — | — | — | — | — | |
| Net Income | 382 | 391 | 226 | — | — | — | — | — | — | |
| EPS (Recurring) | 2.25 | 2.32 | 1.37 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 2.25 | 2.32 | 1.37 | — | — | — | — | — | — | |
| EPS (Diluted) | 2.22 | 2.29 | 1.36 | — | — | — | — | — | — | |
| EBITDA | 116 | 151 | 100 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 12.29 | 11.66 | 13.49 | — | — | — | — | — | — | |
| Price To Sales Ratio | 4.12 | 4.21 | 3.18 | — | — | — | — | — | — | |
| Gross Margin | 91.13 | 91.70 | 91.44 | — | — | — | — | — | — | |
| Operating Margin | 7.55 | 9.79 | 24.11 | — | — | — | — | — | — | |
| Net Margin | 33.54 | 36.47 | 23.59 | — | — | — | — | — | — | |
| Shares Outstanding | 172 | 169 | 166 | — | — | — | — | — | — | |
| Market Capitalization | 4,694 | 4,514 | 3,046 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Aug 06 '26 | Option Exercise | 17.84 | 14,292 | 254,969 | 82,120 | Aug 07 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Aug 06 '26 | Sale | 29.22 | 14,292 | 417,604 | 67,828 | Aug 07 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Aug 05 '26 | Option Exercise | 17.84 | 5,849 | 104,346 | 73,677 | Aug 07 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Aug 05 '26 | Sale | 29.00 | 5,849 | 169,638 | 67,828 | Aug 07 |
| Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | Jul 30 '26 | Sale | 26.13 | 16,558 | 432,663 | 18,994 | Jul 31 |
| Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | Jul 29 '26 | Option Exercise | 0.00 | 32,272 | 0 | 35,552 | Jul 31 |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER | Jun 26 '26 | Sale | 26.08 | 11,421 | 297,912 | 13,088 | Jun 29 |
| GAROFALO ELIZABETH A. | Director | May 29 '26 | Option Exercise | 0.00 | 8,107 | 0 | 33,489 | Jun 01 |
| Daly James M | Director | May 29 '26 | Option Exercise | 0.00 | 8,107 | 0 | 12,148 | Jun 01 |
| HARRIGAN EDMUND | Director | May 29 '26 | Option Exercise | 0.00 | 8,107 | 0 | 43,148 | Jun 01 |
| Ndu Adora | Director | May 29 '26 | Option Exercise | 0.00 | 8,107 | 0 | 32,908 | Jun 01 |
| Brege Laura | Director | May 29 '26 | Option Exercise | 0.00 | 8,107 | 0 | 23,202 | Jun 01 |
| Poole Jonathan | Director | May 29 '26 | Option Exercise | 0.00 | 2,010 | 0 | 2,010 | Jun 01 |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER | May 26 '26 | Sale | 21.18 | 5,401 | 114,393 | 24,509 | May 27 |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER | May 04 '26 | Sale | 21.79 | 1,332 | 29,024 | 29,129 | May 05 |